Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future

Mohammed Faluk, Abdirahman Wardhere, Abdilahi Mohamoud, Mohammed Nor, Dimitrios Bampastsias, Ermioni Oikonomou, Zaid Almubaid, Bashar Al-Hemyari

Research output: Contribution to journalReview articlepeer-review

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Hyperlipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C) is one of the major risk factors for CVD. Major landmark cardiovascular outcome clinical trials demonstrated that LDL-C lowering medications reduce cardiovascular events, and the lower the LDL-C the better the outcome. This article discusses the evolution of LDL-C lowering medications starting from bile acid sequestrants (BAS), statin therapy, bempedoic acid, the proprotein convertase subtilisin kexin 9 (PCSK9) synthesis inhibitor, novel small interfering RNA-based therapy (inclisiran) to the most recent oral PCSK9 inhibitors (MK-0616) which is currently under phase 3 clinical trial studies.

Original languageEnglish (US)
Article number102637
JournalCurrent Problems in Cardiology
Volume49
Issue number7
DOIs
StatePublished - Jul 2024

Keywords

  • Cardiovascular benefits
  • Cholesterol medications
  • LDL-C lowering medications
  • LDL-C medications

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future'. Together they form a unique fingerprint.

Cite this